Brzeziańska Ewa, Pastuszak-Lewandoska Dorota, Wojciechowska Katarzyna, Migdalska-Sek Monika, Cyniak-Magierska Anna, Nawrot Ewa, Lewiński Andrzej
Department of Endocrinology and Metabolic Diseases, Medical University of Lodz, Polish Mother's Memorial Hospital-Research Institute, Rzgowska Street No. 281/289, 93-338 Lodz, Poland.
Neuro Endocrinol Lett. 2007 Aug;28(4):351-9.
Papillary thyroid carcinoma (PTC) is the most common malignancy of the thyroid gland. The high incidence of RET/PTC and Trk rearrangements or point mutations in RAS and c-MET oncogenes are the genetic hallmarks of PTC. Recently, oncogene BRAF has become a subject of great interest. The mutation of BRAF gene is characteristic for PTC and poorly differentiated and/or undifferentiated cancers derived from PTC. The predominant mutation of this gene, reported in PTC, is a single transversion in exon 15 (T1799A), which results in substitution of valine to glutamate at residue 600 (BRAF V600E, formerly position 1796 and residue V599E). It has been proved that the frequency of this mutation in PTC varies within the range of 29% to 69% in different populations.
The aim of this study was to estimate the frequency of BRAF (V600E) mutation in PTC in the Polish population, and to evaluate the possible relationships between the presence of BRAF mutation and such parameters, as patient's age, gender, histopathological variant and the clinical staging of PTC.
Analysis of BRAF (V600E) mutation was performed by single strand conformation polymorphism (SSCP) analysis and real-time allele-specific polymerase chain reaction (ASPCR) in tumour tissues from 25 patients with PTC. We compared the sensitivity of real-time AS-PCR, SSCP method and direct DNA sequencing of PCR products. We used 25 PTC tissues (including the follicular variant of PTC - 8 cases, the classic variant of PTC - 14 cases and the tall-cell variant of PTC - 3 cases).
V600E mutation in BRAF gene was detected in 12/25 (48%) cases of PTC. Mutation screening of exon 15 gene BRAF revealed three types of mutations, i.e. V600E, V600M, and overlapping mutations V600E/V600K. No correlation was found between BRAF mutation and patient's age and sex and particular stage in clinical staging systems (TNM Staging, the University of Chicago clinical class, and Ohio State University Staging). Regarding the histopathological variants of PTC, mutation in BRAF gene was more frequent in classic variant of PTC as compared with follicular variant of PTC.
The real-time AS-PCR method proved to be more sensitive than SSCP and sequencing of PCR products. Our study is the first one in which the frequency of BRAF (V600E) mutation in PTC was reported for the Polish population. Similarly to the results obtained by others, there was no coexistence of BRAF (V600E) mutation and RET/PTC and/or Trk rearrangements or RAS mutation in PTC tissue. Our results do not confirm the relationship between the BRAF (V600E) mutation and the clinical outcome of PTC.
甲状腺乳头状癌(PTC)是甲状腺最常见的恶性肿瘤。RET/PTC的高发生率以及RAS和c-MET癌基因中的Trk重排或点突变是PTC的遗传特征。最近,癌基因BRAF已成为人们极大关注的对象。BRAF基因的突变是PTC以及源自PTC的低分化和/或未分化癌的特征。该基因在PTC中报道的主要突变是外显子15中的单个颠换(T1799A),这导致第600位残基处缬氨酸被谷氨酸替代(BRAF V600E,以前的位置1796和残基V599E)。已证明该突变在PTC中的频率在不同人群中为29%至69%。
本研究的目的是估计波兰人群中PTC中BRAF(V600E)突变的频率,并评估BRAF突变的存在与患者年龄、性别、组织病理学变异和PTC临床分期等参数之间的可能关系。
通过单链构象多态性(SSCP)分析和实时等位基因特异性聚合酶链反应(ASPCR)对25例PTC患者的肿瘤组织进行BRAF(V600E)突变分析。我们比较了实时AS-PCR、SSCP方法和PCR产物直接DNA测序的敏感性。我们使用了25例PTC组织(包括PTC的滤泡变体8例、PTC的经典变体14例和PTC的高细胞变体3例)。
在25例PTC病例中的12例(48%)检测到BRAF基因中的V600E突变。外显子15基因BRAF的突变筛查揭示了三种突变类型,即V600E、V600M和重叠突变V600E/V600K。未发现BRAF突变与患者年龄、性别以及临床分期系统中的特定阶段(TNM分期、芝加哥大学临床分级和俄亥俄州立大学分期)之间存在相关性。关于PTC的组织病理学变异,与PTC的滤泡变体相比,BRAF基因的突变在PTC的经典变体中更频繁。
实时AS-PCR方法被证明比SSCP和PCR产物测序更敏感。我们的研究是首次报道波兰人群中PTC中BRAF(V600E)突变频率的研究。与其他人获得的结果类似,PTC组织中不存在BRAF(V600E)突变与RET/PTC和/或Trk重排或RAS突变的共存。我们的结果未证实BRAF(V600E)突变与PTC临床结果之间的关系。